CenterBook Partners LP purchased a new stake in Boston Scientific Co. (NYSE:BSX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 12,812 shares of the medical equipment provider's stock, valued at approximately $1,144,000.
Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Boston Scientific by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 132,890,784 shares of the medical equipment provider's stock valued at $11,869,805,000 after acquiring an additional 1,600,062 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Boston Scientific by 10.2% during the 4th quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock worth $3,230,293,000 after buying an additional 3,344,571 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Boston Scientific by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 30,626,170 shares of the medical equipment provider's stock valued at $2,729,371,000 after purchasing an additional 1,041,329 shares during the last quarter. Norges Bank bought a new position in Boston Scientific in the fourth quarter valued at approximately $1,762,522,000. Finally, Franklin Resources Inc. raised its position in shares of Boston Scientific by 5.3% during the fourth quarter. Franklin Resources Inc. now owns 16,539,488 shares of the medical equipment provider's stock worth $1,477,307,000 after acquiring an additional 832,386 shares during the last quarter. Institutional investors own 89.07% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on BSX. Argus set a $130.00 target price on shares of Boston Scientific in a research report on Tuesday, February 18th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a report on Friday, January 10th. Truist Financial dropped their price target on Boston Scientific from $120.00 to $113.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. Royal Bank of Canada boosted their price target on shares of Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Finally, Needham & Company LLC upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $113.00 price target on the stock in a research note on Wednesday. One analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $110.22.
Get Our Latest Analysis on BSX
Insider Buying and Selling at Boston Scientific
In other news, Director Edward J. Ludwig sold 12,000 shares of the business's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $105.48, for a total transaction of $1,265,760.00. Following the transaction, the director now owns 24,398 shares in the company, valued at approximately $2,573,501.04. The trade was a 32.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP John Bradley Sorenson sold 6,528 shares of the company's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $104.97, for a total transaction of $685,244.16. Following the transaction, the executive vice president now owns 26,449 shares in the company, valued at approximately $2,776,351.53. This trade represents a 19.80 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 133,183 shares of company stock worth $13,948,476. 0.50% of the stock is owned by company insiders.
Boston Scientific Stock Performance
Shares of BSX stock traded up $1.88 during trading hours on Wednesday, reaching $96.11. 2,855,149 shares of the company traded hands, compared to its average volume of 7,833,592. Boston Scientific Co. has a 12-month low of $66.80 and a 12-month high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The firm has a 50-day moving average price of $100.11 and a 200 day moving average price of $94.18. The company has a market cap of $142.15 billion, a P/E ratio of 76.89, a P/E/G ratio of 2.79 and a beta of 0.73.
Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, sell-side analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.
About Boston Scientific
(
Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Further Reading
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
